Press Releases

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4ee770/lower_barriers_to) has announced the addition of the "Lower Barriers to Entry Will Drive China's Smartphone Market" report to their offering.

Smartphone shipments in China grew 30% to 23.6 million in 2008 despite China's uncertain economy and overall stagnation in handset shipment growth. Mobile Internet applications, GPS, and multimedia functionality have been the most important drivers of this growth.

In-Stat estimates that the compound annual growth rate of China's smartphone market will be 25% throughout the period 2009 to 2013 and that the next wave of smartphone market growth will be driven by lowered barriers-to-entry on both the OS and chipset platform solution sides. This report examines the changing dynamics of China's smartphone OS and chipset platform markets and analyzes how these will drive the smartphone market in coming years. Details of other significant drivers are also provided.

This report includes:

    --  2008 market share for China's smartphone market by vendor and OS
    --  New smartphone models and product design trends
    --  In-depth analysis of smartphone OS market trends, especially with regard
        to Android, Symbian, and OMS
    --  An outline of the current dynamic changes in the smartphone chipset
        platform market
    --  A list of market drivers
    --  Market forecasts through 2013

HIGHLIGHTS

    --  China's smartphone shipments increased 30% in 2008 to 23.6 million units
        and are projected to reach 73.6 million, or 31.5% of total handset
        shipments, by 2013.
    --  The next wave of smartphone market growth will be driven by lower
        barriers to entry with regard to both OS and chipset platform solutions.
    --  Free and complete smartphone software platform from OHA and the Symbian
        Foundation will fuel smartphone market growth in the coming years.
    --  Turnkey chipset platform solutions from Huawei and MediaTek are another
        important factor in lowering barriers to entry.

Key Topics Covered:

Introduction

Definitions

Overview

Smartphone Value Chain Analysis

Drivers and Barriers

Market Forecasts

Methodology

List of Table

List of Figures

Companies Mentioned:

    --  Google
    --  Nokia
    --  Microsoft
    --  Symbian
    --  Linux
    --  MediaTek
    --  Huawei Turnkey

For more information visit http://www.researchandmarkets.com/research/4ee770/lower_barriers_to

    Source: Research and Markets

BATAVIA, N.Y.--(BUSINESS WIRE)-- Graham Corporation (NYSE Amex: GHM) a manufacturer of critical equipment for energy, petrochemical and other process industries, today announced that its quality management system for product design, fabrication and servicing has received certification in accordance with ISO 9001:2008, the world's most widely recognized standard for quality management systems. Although Graham's quality management system has been ISO 9001-compliant since 1999, in recent years Graham has taken additional steps to advance its system to continue to meet the high standards of its customers.

James R. Lines, Graham's President and Chief Executive Officer, commented, "We have a strong commitment to customer satisfaction that is supported by our company-wide strategy for continuous improvement. This commitment led us to add even more rigor to the Graham quality management system. We believe that these process enhancements will enable Graham to continue to create products that meet or exceed customer expectations."

"The credit for this achievement belongs to Graham's employees for the tremendous energy and drive displayed during the certification process. They understand the benefits derived from continuous improvement and are focused on the ultimate goals of achieving superior customer satisfaction and eliminating errors. We strive to create an environment where we do it right the first time, every time," he concluded.

ABOUT GRAHAM CORPORATION

With world-renowned engineering expertise in vacuum and heat transfer technology, Graham Corporation is a global designer, manufacturer and supplier of custom-engineered ejectors, pumps, condensers, vacuum systems and heat exchangers. For over 70 years, Graham has built a reputation for top quality, reliable products and high-standards of customer service. Sold either as components or complete system solutions, the principal markets for Graham's equipment are the energy, petrochemical and other process industries. Graham's equipment can be found in diverse applications, such as metal refining, pulp and paper processing, ship-building, water heating, refrigeration, desalination, food processing, pharmaceutical, heating, ventilating and air conditioning.

Graham Corporation's reach spans the globe. Its equipment is installed in facilities from North and South America to Europe, Asia, Africa and the Middle East. Graham routinely posts news and other important information on its website, www.graham-mfg.com, where additional comprehensive information on the Company can be found.

Safe Harbor Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects," "estimates," "projects," "anticipates," "believes," "could," and other similar words. All statements addressing operating performance, events, or developments that Graham Corporation expects or anticipates will occur in the future, including but not limited to, statements relating to anticipated revenue, profit margins, foreign sales operations, its strategy to build its global sales representative channel, the effectiveness of automation in expanding its engineering capacity, its ability to improve cost competitiveness, customer preferences, changes in market conditions in the industries in which it operates, changes in general economic conditions and customer behavior and its acquisition strategy are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties are more fully described in Graham Corporation's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission, including under the heading entitled "Risk Factors."

Should one or more of these risks or uncertainties materialize, or should any of Graham Corporation's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Graham Corporation's forward-looking statements. Except as required by law, Graham Corporation disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release.

    Source: Graham Corporation

NEW YORK--(BUSINESS WIRE)-- Earlier today in Beijing, the ICBC Mobile Payment American Express(R) Card, China's first dual-currency credit card with mobile account payment capabilities and features, was officially launched by the Industrial and Commercial Bank of China (ICBC), Union Mobile Pay (UMPay) and American Express.

ICBC is the largest commercial bank in the world by assets and profitability, and the largest credit card issuer in China. The ICBC Mobile Payment American Express Card combines the leading credit card platform of ICBC, the advanced mobile e-commerce services of UMPay (a leading mobile payments company in China), and the global merchant network and marketing resources of American Express. The Card signals a new era of collaboration among banks, mobile payment providers and credit card organizations, and will provide unparalleled levels of integration, efficiency and control for Chinese consumers.

The new Card leverages the "anywhere-and-anytime" advantages of mobile phones and the payment advantages of credit cards to provide consumers with secure, convenient, and flexible online, offline, and mobile payment options.

After designating their mobile phone number to their credit card account and activating their mobile payment function, Cardmembers can select merchants accepting mobile payments from their mobile phones, and authorize their payments for digital downloads, utilities, and other online and offline goods. The transactions will be automatically charged to their ICBC Mobile Payment American Express Card accounts. Cardmembers can choose to settle their charges in either US dollar or Renminbi and they don't have to pay those charges until they receive their credit card statement.

"ICBC is the biggest commercial bank in China, and we continue to reinvent our products and services to meet the changing needs of our customers," said Luan Jian Sheng, President and Head of Card Center from ICBC. "ICBC has issued more than 50 million credit cards and is the leading credit card brand in China. By integrating the respective advantages of ICBC, American Express and UMPay, we are able to bring our success in the credit card business to new heights by providing advanced and more convenient payment products to consumers in China."

"As a leading global merchant acquirer and worldwide payment network, American Express believes emerging payments will provide significant potential going forward. We intend to remain active in this space," said Kula Kulendran, American Express Executive Vice President and Head of Global Network Services in Japan, Asia Pacific and Australia.

"China has the largest mobile phone subscriber population in the world, and we are delighted to work with ICBC and UMPay to develop new mobile payment opportunities in this market. The launch of this new Card marks a new milestone for American Express in China. It will bring a new transaction channel, a new marketing tool and, ultimately, all new potential for the business growth of merchants throughout China. We look forward to a long-term, successful partnership," added Kulendran.

"With mobile handset users in China fast approaching 700 million, mobile e-commerce has been a growing consumer need and market trend in China," said Zhang Bin, General Manager of UMPay. "Convenient, prompt, and reliable mobile payment is a pre-requisite for the development of mobile e-commerce. UMPay has market leading infrastructure and know-how in China's mobile e-commerce market. We fully expect the new ICBC Mobile Payment American Express Card to play an important role in the country's mobile payment and e-commerce markets."

About Industrial and Commercial Bank of China

ICBC is the largest wholesale and retail bank in China by assets and deposits and is a market leader in many business areas including corporate and personal loans, deposits, mortgages, e-banking, custodian services and inter-bank clearing. It provides a wide range of commercial banking services to corporate and individual customers. ICBC has approximately 16,000 outlets and employs 382,000 people across China. It had total assets of RMB 11.43 trillion at the end of June, 2009.

About Union Mobile Pay

UMPay is a joint venture founded in August 2003 by China Mobile and China UnionPay. UMPay specializes in mobile payment, providing China Mobile subscribers with innovative payment products such as Mobile Wallet and the Financial Message Service, and allows merchants to enjoy broader, faster and easier payment channels.

About American Express

American Express Company is a leading global payments, network and travel company founded in 1850. Since 1996, American Express has been pursuing a strategy of opening its merchant network and card product portfolio to third party issuers around the world. By leveraging its global infrastructure and the powerful appeal of the brand, American Express has gained even broader reach for its network worldwide. American Express has now established 131 partnerships in 130 markets across the world.

    Source: American Express Company

SWIFTWATER, Pa., Nov. 11 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the final analyses of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults and children.

To view the Multimedia News Release, go to: http://multivu.prnewswire.com/mnr/sanofi_pasteur/41122/

The data confirm the immunogenicity and safety profile of the vaccine, with no serious vaccine-related adverse events reported during the 42 days of follow-up in the two trials.

"These are extremely important data," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur, "because they once again make clear not only the immunogenicity of the Influenza A (H1N1) 2009 Monovalent Vaccine manufactured by Sanofi Pasteur, but also the fact that this vaccine has a safety profile similar to that typically observed with seasonal influenza vaccine in all age groups studied."

The trials confirm that one dose of Influenza A (H1N1) 2009 Monovalent Vaccine induces a robust antibody response in adults -- but two doses of vaccine are needed to assure a robust antibody response in children 9 years of age and younger. The two-dose regimen for these younger children is similar to the recommendations for seasonal influenza immunization in this age group.

About the Trial

The randomized, placebo-controlled, multicenter trials were conducted by Sanofi Pasteur to determine the immunogenicity and safety of the vaccine, given in two doses, with the second dose administered 21 days following the first dose. Immunogenicity was measured at day 21, just prior to administration of the second dose, and again at day 42.

The adult trial was conducted in 849 individuals divided into two age cohorts: 18 through 64 years of age; and 65 years of age and older. Study participants in each age cohort were randomized to four treatment groups. Three groups received a 0.5 mL injection of non-adjuvanted vaccine formulated to contain 7.5, 15 or 30 mcg of hemagglutinin (HA) antigen. The fourth group received a placebo control (ClinicalTrials.gov registration number NCT00953524).

In the pediatric trial, 474 children were enrolled in two age cohorts: 6 months through 35 months of age; and 3 years through 9 years of age. The trial evaluated two vaccine formulations, 7.5 mcg and 15 mcg of HA antigen in each of two cohorts, with a third group receiving a placebo (ClinicalTrials.gov registration number NCT00952419).

At Day 42, 21 days following a second 7.5 mcg dose of Influenza A (H1N1) 2009 Monovalent Vaccine, seroprotection (defined as an antibody titer of 1:40 or greater) was achieved in 92 percent of children 6 months through 35 months of age; and following a second 15 mcg dose of the vaccine, seroprotection was achieved in 99 percent of children 3 through 9 years of age, 99 percent of adults 18 through 64 years of age and in 95 percent of adults age 65 and older.

Sanofi Pasteur previously reported interim data showing that an immune response considered seroprotective was achieved following one 15 mcg dose of the vaccine in 50 percent of children 6 months through 35 months of age, 76 percent of children 3 through 9 years of age, 98 percent of adults 18 through 64 years of age and 92 percent of adults age 65 and older.

A rise in antibody titers lower than 1:40 following vaccination may minimize the occurrence of disease and its consequences but is not considered seroprotective.

The data from these clinical trials provide additional information to guide recommendations on the optimal dosage, number of doses and schedule.

No serious vaccine-related adverse events were reported during the trial. Adverse event monitoring will continue for six months after administration of the second vaccine dose. Solicited systemic and local reactions reported were similar to those observed in other studies of seasonal trivalent inactivated influenza vaccine administered to persons in comparable age groups.

About Influenza A (H1N1) 2009 Monovalent Vaccine

The U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine manufactured by Sanofi Pasteur is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus. Influenza A (H1N1) 2009 Monovalent Vaccine was licensed by the U.S. Food and Drug Administration on September 15 as a monovalent strain change to Sanofi Pasteur's licensed seasonal influenza vaccine.

The Influenza A (H1N1) 2009 Monovalent Vaccine is manufactured by the same process as Sanofi Pasteur's seasonal trivalent influenza virus vaccine licensed in the U.S. Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009 (H1N1) v-like virus. Influenza A (H1N1) 2009 Monovalent Vaccine is licensed for single-dose presentations in syringes and vials and in multi-dose vials. There is no preservative used in the single-dose presentations. Multi-dose vials contain a preservative.

Safety Information for Influenza A (H1N1) 2009 Monovalent Vaccine

Influenza vaccine should not be administered to anyone with a known severe hypersensitivity to egg proteins, any vaccine component or life-threatening reactions after previous administration of any influenza vaccine. Recurrence of Guillain-Barre syndrome (GBS) has been temporally associated with the administration of influenza vaccine. The decision to give Influenza A (H1N1) 2009 Monovalent Vaccine to individuals who have a prior history of GBS should be based on careful consideration of the potential benefits and risks. Vaccination with Influenza A (H1N1) 2009 Monovalent Vaccine may not protect all individuals.

Before administering Influenza A (H1N1) 2009 Monovalent Vaccine, please see full U.S. Prescribing Information at www.vaccineplace.com/products.

About Influenza Vaccine Production at Sanofi Pasteur

Sanofi Pasteur operates influenza vaccine production facilities in Val de Reuil, France and in Swiftwater, Pa. (U.S.). All Sanofi Pasteur influenza vaccine facilities have been designed and built to be able to switch from seasonal influenza vaccine production to pandemic influenza vaccine production.

Sanofi Pasteur produces approximately 40 percent of the influenza vaccines distributed worldwide and more than 45 percent of the influenza vaccines distributed in the U.S. for the 2008-2009 influenza season. More information about Sanofi Pasteur's pandemic preparedness efforts can be found at www.pandemic.influenza.com.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or www.sanofipasteur.us.

Project Funding

This project has been funded with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200900121C. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

SOURCE Sanofi Pasteur

SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/11/09 -- Emergency Management & Safety Solutions (EMS Solutions), the crisis planner for many Fortune 100 companies, international government agencies and large non-profit organizations, is providing free resources to help companies better prepare for and prevent transmission of this year's H1N1 flu pandemic. Today, over 180 countries have experienced the H1N1 virus outbreak and approximately 6,500 people have died -- including over 1,500 in North America, according to the European Center for Disease Prevention and Control.

Illness with the H1N1 virus ranges from mild to severe. Although most people who have been sick have recovered without needing medical treatment, hospitalizations and deaths have occurred from infection with the virus.

Information analyzed by the CDC supports the conclusion that the H1N1 flu has caused a greater disease burden in people younger than 25 years of age than older people. Pregnancy and other previously recognized high-risk medical conditions from seasonal influenza appear to be associated with the increased risk of complications from swine flu. These underlying conditions include asthma, diabetes, suppressed immune systems, heart disease, kidney disease, neuro-cognitive and neuromuscular disorders and pregnancy.

"When planning for a pandemic crisis, companies must include broad thinking about how their supply chains, communications and workforces would be disrupted," says Regina Phelps, President of EMS Solutions. "It is especially important that they enforce procedures such as hand-washing and restricted visitors during the height of an emergency, which experts say could result in an average 30 percent absenteeism."

People on the priority list for the H1N1 vaccine should get it as soon as it is available this fall. Workers who frequently travel both domestically and internationally should receive the vaccine. Also, cautiously distance yourself and loved ones from people at work, school and those you interact with socially.

One of the main concerns for most companies is to prevent high absentee rates. Executives need to consider whether employees would be equipped to work from home during a pandemic, and how to care for employees who may suddenly become seriously ill while at work. In addition, it is recommended that employers should adopt a more relaxed sick-leave policy to prevent sick employees from feeling pressured to show up to work. This includes the consideration of hourly workers, who don't get paid when they don't come to work.

Also, managers should supply staff with antibacterial wipes to clean work areas and telephones. A well thought-out plan is important before it is disseminated to employees, and employers should be sensitive to drawing a fine line between educating people and scaring them.

To help keep up with the facts and statistics of the swine flu, Regina Phelps, R.N., B.S.N., M.P.A., C.E.M., an internationally recognized thought leader and expert in the field of emergency management and continuity planning, updates her H1N1 blog with all the latest news from around the world at: H1N1 - Pandemic Influenza News (http://emssolutionsinc.wordpress.com). Additionally, Phelps has begun a new series of pandemic awareness videos, which can be found on YouTube (www.youtube.com/watch?v=1JAJ5KTJXfU), and you can follow her pandemic conference updates on Facebook (www.facebook.com/regina.phelps). For more resources on pandemic planning for businesses, including podcasts, employee educational tools, flu symptoms and posters you could display in your workplace, please visit: www.ems-solutionsinc.com/climatechange.html and http://www.ems-solutionsinc.com/handouts.html.

With over 27 years of experience, EMS Solutions has written hundreds of pandemic plans and conducted over 300 pandemic exercises for some of the largest global companies. Emergency Management & Safety Solutions is an internationally recognized firm in the field of emergency management, pandemic and business continuity planning. Established in 1982, the firm has provided consultation, training and educational speaking services to corporations, government agencies and non-profit organizations. Select clients include AEGON, Research in Motion, Liberty Mutual, Northern Trust, Macy's Inc., VISA Inc., Triton Container, Duke University, Stanford University, Lam Research, MasterCard, Caltech Institute, International Finance Corporation (IFC), United States Social Security Administration, Gilead and The World Bank.

Photo Available via E-mail

Add to Digg Bookmark with del.icio.us Add to Newsvine

CONTACT:
Gary Pike, APR
(415) 585-2100
Email Contact